Dr Jacky Vonderscher, PhD, co-founder and Chief Executive Officer

Jacky Vonderscher

  • Founder of Vonderscher&Co GmbH
  • Senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Senior VP Head of Translation Research Sciences at Roche in USA and Switzerland (2010-2012)
  • Senior VP head of Molecular Medicine Labs at Roche (2008-2010)
  • Previously held other senior positions with Novartis in the USA and Switzerland (1979 to 2008)
  • Known for his leading role in the discovery and development of Sandimmum Neoral® in the 90s
  • Co-inventor on the first patents of Mycophenolic Acid Sodium salt (Myfortic® Product) and of Everolimus (Certican® and Afinitor® Products)
  • Board member of Inatherys and ObsEva and SAB member of Inotrem

Laurène Meyniel-Schicklin, Engineer, co-founder and Head of Bioinformatics

Laurène Meyniel-Schicklin

  • Engineer in Biology and Computer Science (Genopole, Evry)
  • Project leader in bioinformatics since 2007
  • More than 10 years experience in omics data management and analysis for drug discovery
  • 18 publications, inventor on 3 patents
  • Forbes: Top 50 Women in Tech 2018

Dr Benoît de Chassey, PhD, co-founder and Head of Drug Discovery Platform

Benoît de Chassey

  • Principal Investigator of the project since 2006
  • 17 years experience in high-throughput approaches in drug discovery
  • Former project leader in functional screenings at Aptanomics
  • 22 publications, inventor on 7 patents

Pr Patrice André, MD, PhD, co-founder and Medical Advisor

Patrice André

  • Professor of Virology, Charles Mérieux Lyon Sud Medical School, Lyon 1 University
  • Head of clinical virology department at the Hospices Civils de Lyon
  • Team leader at the International Center for Infectiology Research
  • Post-doctoral fellow at New Mexico University
  • > 200 publications in international peer review and high-impact journals, inventor on 7 patents
  • Former member at several scientific committees (Hospices Civils de Lyon, Inserm)
  • Former expert at AFSSAPS
  • Member of several ANRS commissions

Dr Vincent Lotteau, PhD, co-founder and Scientific Advisor

Vincent Lotteau

  • Inserm Research Director, Immunologist
  • Team leader at the International Center for Infectiology Research
  • Member of the Laboratory of Excellence “Ecofect”
  • Founder of the technology transfer team
  • Former director of Inserm Unit « Fundamental and clinical immunology »
  • Former member of Inserm-Transfert steering committee
  • Participated to several governmental missions
  • Post-doctoral fellow at Harvard University and Scripps Clinic Research Foundation
  • Inventor on 9 patents
  • European expert for systems biology

Dr Jean-Jacques Garaud, MD, co-founder

Jean-Jacques Garaud

  • Founder/CEO of ADV Life Science SA
  • CEO of Inotrem SA
  • A senior executive with a broad R&D experience in the pharmaceutical industry
  • Most recently Executive VP Head of Pharma Research and Early Development at Roche (2010 to 2012)
  • Executive VP Head of Development and Chief Medical Officer at Roche (2007 to 2010)
  • Previously held other senior positions with Shering-Plough in the USA (1991 to 2001) and with Novartis in the USA and Switzerland (2001 to 2007)
  • Known for his leading role in the development of Interferon alpha, ribavirin and PEG-interferon in hepatitis C virus in the 90s
  • Board member of Circassia, Polyphor, MedDay and Inatherys

Inserm Transfert Initiative, co-founder

Inserm Transfert Initiative

  • Created in 2005, Inserm Transfert Initiative is a seed-capital company with € 39.7 M capital, further to its second fund raising in 2012.
  • It focuses on providing seed capital for innovative young companies in the biomedical field. Inserm Transfert Initiative supports biotech entrepreneurs in the early stages of their companies’ development.
  • Its current shareholders are BPI France, Inserm Transfert SA, AbbVie, Boehringer Ingelheim Venture Fund, GlaxoSmithKline, Ipsen, LFB, MSD (Merck & Co), Natixis Venture Selection, Pfizer, Sanofi, SHAM, Shire, Sofinnova Partners.